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Natural killer cells are a group of lymphocytes which function as tightly controlled surveillance operatives which identify
transformed cells through a discrete balance of activating and inhibitory receptors ultimately leading to the destruction of
incongruent cells. The understanding of this ﬁnely tuned balancing act has been aided by the high-resolution structure
determination of activating and inhibitory receptors both alone and in complex with their ligands. This paper collates these
structural studies detailing the aspects which directly relate to the natural killer cell function and serves to inform both the
specialized structural biologist reader and a more general immunology audience.
1.Introduction
T h ef u n c t i o n a lo u t c o m eo fN a t u r a lK i l l e r( N K )c e l l si s
determined by integrating both activating and inhibitory
signals resulting in a highly controlled response which medi-
ates cytotoxicity against transformed cells and, in addition,
the release of cytokines critical to the immune response.
At the center of this balance resides a group of receptors
that allow the relay of intracellular signaling via intrinsic
or associated cytoplasmic molecular motifs for various
kinases or phosphatases [1–4]. The list of identiﬁed NK cell
activating and inhibitory receptors currently exceeds twenty.
In humans, the activating NK receptors include CD16, the
short-tail members of killer immunoglobulin-like receptors
(KIRs), CD94/NKG2C, NKG2D, 2B4, NKp30, NKp44, and
NKp46 (Figure 1). They signal through association with
either DAP10 which allows PI3-kinase activation or DAP12,
CD3ζ,o rF c εRIγ, which all contain immunotyrosine-based
activation motifs (ITAM). In addition, adhesion molecules,
such as LFA-1 and DNAM-1, are also important for the
lytic function of NK cells, but they do not associate
directly with the known ITAM-containing molecules [5].
The inhibitory NK receptors include the long-tail mem-
bers of the KIR family, CD94/NKG2A, leukocyte-associated
immunoglobulin-like receptor-1 (LAIR-1), and killer cell
lectin-like receptor subfamily G member 1 (KLRG-1) which
signal via cytoplasmic immunotyrosine-based inhibitory
motifs (ITIM). From a structural perspective, all known NK
receptors adopt either an immunoglobulin- (Ig-) like or a C-
type lectin-like receptor fold with both folds present in the
activatingandinhibitoryreceptorfamilies.Inthelastdecade,
a large amount of structural information for many of these
receptors has become available, and this review focuses on
the structures of human NK cell receptors and their ligand
recognition (Table 1).
2.Immunoglobulin-LikeNK Receptors
2.1. Structure of KIR. Shortly after the identiﬁcation of
inhibitory NK cell receptors and their MHC ligands, ques-
tions regarding the mechanisms of ligand recognition were
raised. Prior to the NK cell receptor ligand ﬁndings, T cell
receptors were the only MHC binding molecules. Charac-
terization of the TCR-MHC recognition mechanism was a
central tenet in molecular immunology. The fundamental
principle of TCR-MHC recognition is based on a number
of factors which include the presentation of peptides by a
MHC molecule and the polymorphic MHC residues which2 Journal of Biomedicine and Biotechnology
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Figure 1: Overview of the structurally characterized activating and inhibitory human NK receptors and their ligands. The upper panel
displays the chief activating receptors found on human NK cells including the homodimer NKG2D, the natural cytotoxicity receptors,
NKp46, NKp44, and NKp30, the c-type lectin heterodimer CD94:NKG2C, the Fc receptor CD16, and also the KIR activating receptors. The
associated cytoplasmic signaling molecules for these activating receptors which include DAP12, DAP10, and CD3ζ/FcεRIγ and the speciﬁc
transmembrane residues which facilitate the interaction are also shown. The lower panel illustrates the structurally characterized inhibitory
receptors found on NK cells. These include the KIR receptors KIR 2DL1 and KIR 2DL2 which have been characterized in complex with
peptide bound MHC class I molecules, the heterodimeric CD94:NKG2A which binds to peptide bound HLA-E. The C-type lectin receptor
KLRG-1 which binds to cadherin and the NK cell receptor LAIR-1 molecule which binds to collagen are also shown. The known ligands for
both the activating and inhibitory receptors are illustrated above their respective NK cell receptor.
together interact with the TCR. In addition, the TCR uses
complementarity determining regions (CDR) to recognize
MHC molecules, in a similar manner to that seen with anti-
body ligand interactions. These CDR regions are the result
of gene rearrangement and recombination, thus essentially
allowing an unlimited number of TCR speciﬁcities. This
diverse receptor repertoire is necessary to recognize variable
pathogenic peptides and the presenting polymorphic MHC
moleculeswhichaltogetherenableexquisiteTCR-MHCallele
speciﬁcities.
The identiﬁcation of NK receptors which could bind to
MHC molecules immediately challenged our understanding
of MHC recognition. While the potential T cell receptor
repertoire can be greater than 106 molecules, NK receptorsJournal of Biomedicine and Biotechnology 3
Table 1: List of human NK receptor structures.
Structure Resolution (˚ A) PDB entry Reference
KIR2DL1 1.7 1NKR Fan et al. [6]
KIR2DL2 2.9 2DLI Snyder et al. [10]
2DL2
KIR2DL3 3.0 1B6U Maenaka et al. [8]
KIR2DS2 2.3 1M4K Saulquin et al. [9]
KIR2DS4 2.5 3H8N Graef et al. [7]
KIR2DL2/HLA-Cw3 3.0 1EFX Boyington et al. [11]
KIR2DL1/HLA-Cw4 2.8 1IM9 Fan et al. [12]
NKp46 2.2 1P6F Foster et al. [13]
1.9 1OLL Ponassi et al. [14]
NKp44 2.2 1HKF Cantoni et al. [15]
NKp30 1.8 3NOI Joyce et al. [16]
LAIR-1 1.8 3KGR Brondijk et al., 2010
CD94 2.6 1B6E Boyington et al. [17]
CD94/NKG2A 2.5 3BDW Sullivan et al. [18]
CD94/NKG2A/HLA-E 2.5 3CDG Petrie et al. [19]
3.4 3CII Kaiser et al. [20]
NKG2D 1.95 1HQ8 Wolan et al. [21]
NKG2D/MICA 2.7 1HYR Li et al. [22]
NKG2D/ULBP3 2.6 1KCG Radaev et al. [23]
NKG2D/Rae-1β 3.5 1JSK Li et al. [24]
KLRG1/E-cadherin 1.8 3FF7 Li et al. [25]
DAP12/NKG2C NMR 2L35 Call et al. [26]
are germ-line encoded and there are less than a dozen KIR
molecules in a given individual. A number of questions arose
such as how can such a small number of KIRs recognize a
much larger number of peptide-MHC molecules? While the
KIRgenesarealsomembersoftheIgsuperfamily,couldthey
form TCR-like structures and recognize MHC molecules in a
similar fashion to the TCRs even though the putative CDRs
are nonvariable?
Broadly speaking, there are overall large diﬀerences
between the size and structures of TCR molecules compared
to the KIR molecules. TCR molecules are made up of a
heterodimer of an alpha and beta chain each constituting
∼200 amino acids in length and peptide-MHC recognition is
dictated by both the alpha and beta chains while in contrast
KIR molecules are monomeric consisting of ∼200 amino
acids in length. To date, there are ﬁve crystal structures
available for KIR family members, KIR2DL1, KIR2DL2,
KIR2DL3, KIR2DS2, and KIR2DS4 [6–10]. All structures
display essentially the same fold with two C2-type Ig-like
domains, each made up of a β-sandwich with strands ABE
packed against C CFGA  (Figure 2; note that in contrast to
C2-type Ig-domains, a C1-type Ig-like domain is made up
of ABED strands stacking against CFG strands). The two
Ig-like domains, named D1 and D2, exhibit a tilted side by
side arrangement with a major hinge region, which results
in a substantial surface buried area between the D1 and
D2 domains. The hinge angle observed in the structure of
KIR2DL1 was about 65◦, substantially smaller than those
in the other four structures, which were about 80◦,w h i c h
indicated that the hinge angle might be important for
ligand binding. However, the hinge angle of KIR2DL1 in the
presence of bound HLA molecule was found to be similar
to that of KIR2DL2, suggesting that the smaller hinge angle
observed in the ligand-free structure of KIR 2DL1 is likely
inﬂuenced by crystal packing. Many of the hinge residues are
conserved among members of the KIR family, including the
threedomainKIRs,suggestingtheyallsharethesamerelative
domain arrangement. It is worth noting, however, that there
is no structure available at present for any member of the
KIR3D receptors which diﬀer from the KIR2D molecules by
the presence of an additional D0 domain.
2.2. KIR Recognition of MHC Molecules. Understanding KIR
recognition of MHC molecules through the mapping of
mutational data on the KIR structure suggested that critical
MHC contact regions were not at the tip of the KIR D1
domain as is the case with TCR receptor binding, rather they
were located near the receptor hinge region [6, 10]. Further-
more, while KIRs were known to recognize degenerate MHC
ligands,theligandrecognitionwasnotentirelypromiscuous,
but in fact rather speciﬁc. That is, KIR2DL2 has C1-type
speciﬁcity (KIR molecule contains Lys-44 and binds to Asn-
80 residue in HLA-molecule) recognizing HLA-Cw1, 3, 7,
and 8. In contrast, KIR2DL1 has C2-type speciﬁcity (KIR
molecule contains Met-44 and binds to Lys-80 residue in
HLA molecule) binding to the ligands HLA-Cw2, 4, 5, 6,
and 15. How can MHC molecules with their polymorphic
heavy chains which are necessary for presenting variable4 Journal of Biomedicine and Biotechnology
KIR2DL2
(b)
(c)
(d)
D1 D2
KIR2DL2
HLA-Cw3
HLA-Cw3
HLA-Cw4
(a)
β2m
KIR2DL1
KIR2DL2
α1
α1 α2
α2
K44
N80
M44
K80
Figure 2: Structure of inhibitory KIR molecules. (a) Structure of KIR2DL2 which is made up of two C2-like domains is shown in
cartoon representation with the N-terminus and C-terminus described by a blue and red sphere, respectively. (b) Structure of KIR2DL2
in complex with the MHC class I molecule HLA-Cw3 and β2m shown in cartoon representation with bound peptide shown in ball and
stick representation with yellow carbon atoms. (c) Closeup of the HLA-Cw3:KIR2DL2 interface with interacting residues displayed in ball
and stick representation. The bound peptide is shown with yellow colored carbon atoms while the interacting residues from HLA-Cw3 are
shown in purple and those from the KIR molecule are shown in oﬀ-white coloring. The critical residues for HLA-KIR speciﬁcity, K44 from
KIR 2DL2 and N80 from HLA Cw3 are shown in green and light-blue, respectively. (d) Closeup of the HLA-Cw4:KIR2DL1 interface with
interacting residues displayed in ball and stick representation. The bound peptide is shown with white carbon atoms while the interacting
residues from HLA-Cw4 have green carbon atoms and those from KIR 2DL1 have yellow carbon atoms. The critical residues for HLA-KIR
speciﬁcity, M44 from KIR 2DL1, and K80 from HLA Cw4 are shown in dark green and light green, respectively.
peptides, and whose recognition requires variable regions of
TCR, serve as ligands to nonvariable KIR receptors? These
principle deﬁning questions prompted an intense eﬀort to
resolve the structure of KIR in complex with HLA ligands.
The ﬁrst KIR-MHC complex structure was determined
b e t w e e nK I R 2 D L 2a n dH L A - C w 3b o u n dt oan o n a m e rs e l f -
peptide from human importin-α1[ 11]. Subsequently, the
structure of KIR2DL1 in complex with HLA-Cw4 was also
determined [12]. Since the two KIR receptors recognize
diﬀerent class I MHC allotypes, the structure solution of
both KIR-MHC complexes provided a rather complete and
complementary structural view of both the overall KIR-
MHC recognition and the speciﬁc interactions critical to
their class I MHC speciﬁcities. The overall KIR binding
mode used for HLA recognition is very similar between the
two complexes. Both KIR2DL1 and KIR2DL2 bind to the
peptide-binding groove of the MHC molecules using the
receptorD1andD2domainswhichinteractwiththeα1-andJournal of Biomedicine and Biotechnology 5
α2-helicesoftheMHCheavychain,respectively(Figures2(c)
and 2(d)). Although many detailed interface interactions
diﬀer between the two KIR-MHC complexes, both KIRs
recognize their MHC ligands through primarily salt bridges
and charge complementarity rather than hydrophobic inter-
actions and shape complementarity. KIR receptors contact
primarily nonpolymorphic HLA residues on both the α1-
and α2-helices. The molecular mechanism of the C1- and C2
allotype speciﬁcities of KIR also became apparent. KIR2DL2
can be switched to recognize C2 ligands by just one amino
acid mutation at residue 44 [27]. Similarly, the C1 and C2
type class I ligand engagement appeared to be controlled by
residue 80 on the MHC heavy chain [28]. The structures
suggest that this speciﬁcity switch is due to primarily the
compatibility of one hydrogen bond between Lys 44 of KIR
2DL2 and Asn 80 of HLA-Cw3 [11].
The overall KIR docking orientation on the MHC
molecule is very similar to that of TCR with the D1 and D2
domains of KIRs occupying equivalent positions to the Vα
and Vβ of a TCR. However, KIR receptor binding to the
peptide is altered in comparison to TCR binding. Typically
peptides which are bound to the MHC class I molecules
are 8–10 amino acids in size and they are numbered from
N-terminus to C-terminus with the ﬁrst peptide amino acid
named P1 and so on. TCR binding interactions with the
peptide are primarily centered on the P4-P5 amino acids
and are highly speciﬁc while KIR binding is shifted towards
the C-terminus of the bound peptide interacting with the
P7 and P8 residues of the peptide. This results in a mutually
exclusive region of peptide binding between KIR and TCR
but also some level of overlap. This partial overlap between
KIR and TCR is potentially important to avoid conﬂicting
simultaneous recognition by both the activating T and
inhibitory NK cell receptors. The nonoverlapping peptide
regions used in KIR and TCR binding mechanisms allows
a TCR to evolve and mature against the variable parts of
presented peptides and also the polymorphic MHC residues
while KIR maintains a dual recognition mechanism of both
the nonpolymorphic MHC residues and bound self-peptides
via its speciﬁc binding mechanism ultimately resulting in
inhibition of NK cell activation pathways.
ThepeptidesensitivityofKIR-MHCrecognitionremains
an important issue. While the structures show that KIR
receptors either directly or through water molecules interact
with the MHC bound peptide, the KIR-peptide interactions
only serve to constrain the type of residues placed at the P7
and P8 position of the peptide instead of formally deﬁning
speciﬁc contacts. In the case of KIR2DL2, the receptor and
peptide contact requires a hydrophobic residue at the P7 and
the presence of a small amino acid, such as an Ala or Ser
residue at the P8 position [11]. Whether such constraints
contribute to KIR diﬀerentiation of self versus pathogenic
peptides remains an open question. Since the peptide posi-
tions recognized by KIR are not involved in TCR binding, it
is thus likely that a self-peptide presenting an MHC ligand
of KIR can also present pathogenic peptides for TCR. In
otherwords,MHCmoleculescanevolvesimultaneouslywith
abilities both to rapidly mutate their polymorphic regions to
match and present pathogenic antigens for T cell-mediated
immunity and also to maintain the nonvariant regions for
self peptide binding and recognition by KIR for NK cell
mediated immune protection.
2.3. Activating Killer Ig-Like Receptors. While the inhibitory
group of KIR molecules has been extensively studied, the
function and ligands of the activating KIR molecules are less
well understood. Activating KIR molecules occur less com-
monly than the inhibitory KIR receptors and are comprised
of the two domain KIR2DS family and the three domain
KIR3DS family. KIR2DS1 has similar binding speciﬁcity
to KIR2DL1 in that both bind to HLA-C2 but KIR2DS1
has a much lower aﬃnity for this receptor. Illustrating the
lack of understanding of these receptors is the fact that the
ligands for KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1 are
currently unknown.
Sequence comparison between activating and inhibitory
ligands indicates that the activating and inhibitory molecules
can be shockingly close in sequence identity to each other
but the most minimal changes still result in diﬀerences
in ligand binding speciﬁcity and aﬃnity. One example is
the case of KIR2DS2 in which the ligand speciﬁcity is
unknownwhilethisactivatingmoleculehasbeenstructurally
characterized[9].ThesequencediﬀerencebetweenKIR2DS2
andKIR2DL3isonlytwoaminoacidchangeswithTyr45and
Glu35 found in KIR2DS2 as opposed to Phe45 and Gln35 in
KIR2DL3. The ligand for KIR2DL3 is known to be HLA-C
molecules but KIR2DS2 has undetectable binding aﬃnity for
thesemolecules.KIR2DS2diﬀersinsequencefromKIR2DL2
by four amino acids as follows, P16R, Y45F, R148C, and
T200I. The F45Y change in KIR2DS2 does not lead to any
steric clashes based on modeling of bound HLA molecule
but it will clearly disrupt extensive hydrophobic interactions
which are seen in the 2DL2 structure perhaps explaining the
absence of HLA-C binding (Figures 3(b) and 3(f)).
A second activating KIR, KIR2DS4, has recently been
characterized as an HLA class I receptor which binds
speciﬁcally to subsets of C1+ and C2+ HLA-C and also
to HLA-A∗11 molecules [7]. The presence of activating
KIR molecules appears to occur late in evolution and only
KIR2DS4 has a homologue in any other species [29]. The
structure of this activating KIR molecule KIR2DS4 has also
been determined [7]; (Figure 3). Overall, the structure of
KIR2DS4 is very similar to other KIR molecules as judged
by very low rmsd values (KIR2DL1 bound structure: rmsd
1.04 ˚ A; KIR2DL2 bound structure: rmsd 1.12 ˚ A; KIR2DS2:
rmsd 2.37 ˚ A). KIR2DS4 D1/D2 domains form an angle of
69◦ which is similar to the unbound KIR2DL1 structure
(66◦) but contrasts with the KIR2DL2 (81◦) and KIR2DL3
(78◦)structures.Furtheranalysisofthehingeregionresidues
illustrates a core hydrophobic region which is made up
of 13 amino acids and is very similar to the inhibitory
KIR molecules. Of these residues, only residue 102 shows
some variability amongst the KIR family, and this has been
shown to lead to changes in HLA speciﬁcity implying the
hinge region hydrophobic core can indirectly impact ligand
speciﬁcity and binding. Comparison of KIR2DS4 with other
KIR molecules indicates that the main structural changes
include the altered orientation of residues 43–45 away from6 Journal of Biomedicine and Biotechnology
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Figure 3: Structure of activating KIR receptors. (a) KIR2DS2 shown in cartoon representation with residues likely important for ligand
bindingand also thehinge region residues shown in ball and stick representation. (b)Charged surface representation of the membrane distal
face (binding face) of KIR2DS2. (c) KIR2DS4 shown in cartoon representation with ligand binding and hinge region residues shown in ball
and stick representation. (d) Charged surface representation of the membrane distal face (binding face) of KIR2DS4. (e) For comparative
purposes, the inhibitory receptor KIR2DL2 is shown in cartoon representation with ligand binding and hinge region residues shown in ball
and stick representation. (f) Charged surface representation of the membrane distal face (binding face) of the inhibitory receptor KIR2DL2.
the ligand binding area which results in the critical Lys44
of inhibitory KIRs lying ∼2.5 ˚ A away from the location
observed in KIR2DL2/3. A second critical region is the
Pro71-Val72 region which diﬀers from the KIR2DL2 Gln71-
Asp72 residues and is likely one of the main speciﬁcity
components for KIR2DS4.
The presence of activating receptors with such close lig-
and speciﬁcity to the inhibitory KIR molecules is somewhat
perplexing, but analysis of the presence of these genes in
diﬀerent populations indicates that KIR2DS4 may play a role
in EBV control within Southeast Asian populations [30].
There is also support for the role of activating receptors in
the control of cytomegalovirus infection following kidney
transplantation [31]. The presence of paired or balancing
KIR receptors may exist to prevent viral mutations which
would result in uncontrolled infections. An additional role
of activating KIR receptors in embryo implantation and the
initial stages of pregnancy has been illuminated by Moﬀett
and coworkers [32]. Their studies indicate that the presence
of the activating KIR2DS1 receptor may inﬂuence embryo
implantation and prevent reproductive failure.
2.4. Natural Cytotoxicity Receptors. The natural cytotoxicity
r e c e p t o r sh a v eb e e ni d e n t i ﬁ e da st h ee ﬀector molecules
responsibleforthemajorityofNKdrivencytotoxicityagainst
tumor cells or virally infected cells with blocking of these
receptors resulting in signiﬁcantly decreased NK cell killing
[33]. The NCRs are made up of three Ig-like proteins
named NKp46, NKp30, and NKp44. NKp46 and NKp30
are constitutively expressed on NK cells while NKp44 is
expr esseduponIL -2dri v enacti vationofNKc ells.T odate,all
threeproteinshavebeenstructurallycharacterized(Figure 4)
but some controversy still surrounds their ligands due to the
absence of ligand bound structures.
NKp46 was ﬁrst identiﬁed by Moretta and coworkers in
1997 as a cell surface receptor expressed on freshly isolated
and activated NK cells and which plays a pivotal role in
natural cytotoxicity and targeting of transformed cells [34].
NKp46 is critical to NK cell activation in response to New-
castle disease virus [35], primary tumor melanocytes [36],
urothelial cancers [37], medulloblastoma [38], myeloma
cancer [39], ﬁlovirus infected dendritic cells [40], Herpes
simplex virus [41], vaccinia virus [42], inﬂuenza virus,
parainﬂuenza and sendai viruses [43], and the response
to mycobacterium tuberculosis infected monocytes [44].
N K p 4 6i sat y p eIm e m b r a n ep r o t e i nm a d eu po ft w o
N-terminal Ig-like extracellular domains, a 40 amino acid
linker region, single transmembrane domain, and a short
highly charged 25 amino acid cytoplasmic region. NKp46
contains three glycosylation sites, two which are located in
the 40 amino acid stalk region and one in the D2 domain at
Thr 225. NKp46 lacks an activating cytoplasmic component
but through a transmembrane Arg residue associates with
CD3ζ and FcεRIγ which can transmit a cell activating signal
via their multiple ITAM containing domains. A number of
viral hemagglutinin, neuraminidase-hemagglutinin proteins
which become surface expressed following viral infection
have been proposed as ligands. In addition, Vimentin bind-
ing by NKp46 following mycobacteria infection of mono-
cytes has been described [44]. NKp46 binding of speciﬁc
heparan sulfate proteoglycans has also been proposed as a
ligand and may be critical for tumor cell killing but its
relevance to virally infected cell killing is unclear [45, 46].
The structure of NKp46 was determined by X-ray
crystallography in 2003 [13, 14]r e v e a l i n gas t r u c t u r em a d e
up of two C2-type Ig-like domains (Figure 4). Each domain
is made up of eight β-strands which form two β-sheets
with a typical disulphide bond formed between each sheetJournal of Biomedicine and Biotechnology 7
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Figure 4: Structures of the natural cytotoxicity Receptors in cartoon representation; (a) NKp46, (b) NKp30 (c) NKp44. (d) Structure of
human LAIR-1 with collagen binding residues shown in ball and stick representation.
maintaining the Ig-domain fold. The two domains are
maintained at an angle of 85◦ respective to each other by
a large number of hydrophobic interactions and extensive
hydrogen bonding. An area of 1021 ˚ A is buried between the
two NKp46 domains illustrating the extensive interactions
and within the core region of the domain interactions,
11 of 18 amino acids are conserved in NKp46 sequences
from diverse species. Although associated by function with
NKp30 and NKp44, NKp46 shows very low homology to
the other natural cytotoxicity receptors (Figure 4). The most
structurally similar molecules to NKp46 include the KIR
family of proteins, ILT2 ([47]r m s d :2 . 2˚ A, hinge angle:
86◦), glycoprotein VI ([48]r m s d :1 . 6˚ A, hinge angle: 90◦),
and also FcαRI ([49] CD89; rmsd: 2.4 ˚ A; hinge angle:
92◦). The majority of these homologous molecules have
been structurally deﬁned in complex with their respective
ligands. All of these molecules have a very similar overall
fold made up of two C2 type Ig-like domains and a hinge
angle comparable to that observed in NKp46 (Figure 5).
Altogether, the description of the binding sites of these
homologous proteins suggests that NKp46 would also utilize
the hinge region for ligand binding and the description of a
ligand binding site as determined from structural studies or
large-scale mutagenesis is eagerly anticipated.
NKp44 is a natural cytotoxicity receptor which is found
on activated NK cells and leads to enhanced killing of both
tumor cells and virally infected cells [50–52]. NKp44 is made
up of a single extracellular IgV domain with a 64 amino
acid stalk region which contains a number of glycosylation
sites, a transmembrane region containing a lys residue, and a
shortcytoplasmicdomain.FollowingNKp44ligandbinding,
NK cell activation signals are transduced via DAP12 which
associates with NKp44 through its transmembrane domain.
The crystal structure of the extracellular domain of NKp44
displays a compact V domain structure [15]. It is made up of
two typical β-sheets constructing the Ig-V domain structure.
Unique features of this structure include the presence of
a second disulphide bond which in combination with the
atypical orientation of the equivalent CDR3 loop region
creates a large grooved area on one face of the protein.8 Journal of Biomedicine and Biotechnology
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Figure 5: Structures of NKp46 homologous proteins ((a), (b)) FcαRI, ((c), (d)) KIR2DL2, ((e), (f)) ILT2, and ((g), (h)) GP VI shown in
cartoon representation with transparent surface also shown. The known ligand binding residues of these molecules are given in ball and
stick representation with the surface of these amino acids also highlighted. KIR binding to MHC molecules utilizes a number of residues
found in the AB, CC , EF loop regions of D1, the GA hinge region between D1 and D2, and the BC loop and FG loop regions of D2. ILT-2
uses residues located in the C strand, the CE loop region, EF loop region, and G strand of D1 while also using residues located in the BC
loop region of D2. GP VI utilizes residues in the CC  loop, C strand, CE loop, E strand, EF loop, and F strand of D1 while also using the FG
loop region of D2. CD89 uses residues from the BC loop, C  strand, C E loop, and the FG loop of D1 in a side-on mechanism of binding
in contrast to the other homologous proteins which all utilize the membrane distal face of the receptor for ligand binding. The lower panel
shows the respective molecules in an “above-cell view” orientation which also highlights their ligand binding sites.
NKp44 Sialoadhesin
TREM-1 TLT-1 pIgR
Figure 6:ChargedsurfacerepresentationofNKp44andcloselyrelatedhomologuessialoadhesin,pIgR,TLT-1,andTREM-1.Theorientation
of each molecule is identical to that of NKp44 shown in Figure 4 a n da l l o w sav i e wo ft h eG ,F ,C ,a n dC   sheets of each molecule.
This groove is also positively charged and has been proposed
as a ligand binding site. The NKp44 structure is homologous
to a number of other Ig-like structures including TREM-1
(triggering receptor expressed on myeloid cells; rmsd: 2.0 ˚ A)
[53, 54], TREM-like transcript-1 (rmsd: 1.7 ˚ A) [55], poly Ig
receptor (rmsd: 2.1 ˚ A) [56], sialoadhesin (rmsd: 2.4 ˚ A) [57],
and IREM-1 (inhibitory receptor expressed on myeloid cells,
rmsd: 2.58 ˚ A) [58]( Figure 6).
NKp44 binding to inﬂuenza hemagglutinin and other
viral hemagglutinin-neuraminidase proteins due to the
presence of sialic acid in the NKp44 stalk region have been
presented in the literature [35, 50]. Since NKp44 is alsoJournal of Biomedicine and Biotechnology 9
involvedintheincreasedlysisoftumorcells,itwilllikelybind
to a cellular ligand utilizing its Ig-like domain. In addition
to transformed cells, NKp44 has also been shown to bind
to the cell surface of mycobacteria and other bacteria which
maycontainasimilarorhomologousligandtothatfoundon
human cells [59].
The most recently discovered NCR is NKp30 which was
identiﬁed by Moretta and coworkers [60]. NKp30 has been
shown to be the dominant activating receptor responsible
for the lysis of a number of tumor cell types [60]. In
addition, NKp30 has been shown to cause the activation and
expansion of resting NK cells upon interaction with DCs
and to cause the death of imDCs [61]. NKp30 has a single
extracellularIg-likedomainwithashortstalkregion(∼5aa),
and a transmembrane domain which associates with CD3ζ
homodimers through a charged transmembrane interaction.
The physiological ligands for NKp30 remain a controversial
issue as a large number of NKp30 interacting molecules have
been proposed. These include a human cytomegalovirus
tegument protein pp65 [62], duﬀy-binding-like- (DBL-) 1α
of Plasmodium falciparum erythrocyte membrane protein-
1( PfEMP-1) [63], leukocyte antigen-B-associated transcript
3( B A T 3 )[ 64, 65], and a group of heparan sulfate/heparin
molecules [45]. Most recently, NKp30 was shown to recog-
nize a B7 family homolog (B7-H6) as its ligand [66]. Unlike
the other protein ligands proposed, B7-H6 is expressed
on a number of tumor cell lines, such as K562 and Raji,
as well as on primary cancer cells. However, the lack of
structural information for NKp30 makes it diﬃcult to
parse out the most important ligand involved in cancer
destruction from those proposed. The structure of NKp30
was recently, determined within our group and is shown to
be a single I-type Ig-like domain [16]. The structure displays
strong structural similarity to the CD28 family of receptors.
MutagenesisworkcarriedoutonNKp30andbinding studies
on the B7H6 ligand indicates that binding is very similar
to that observed for PD-1/PD-L1 interactions and involves
residues found on the upper portion of the F and C strands.
2.5. The Structure of LAIR-1. The inhibitory receptor LAIR-
1 is found on a large number of immune cells including
NK cells and is speciﬁcally involved in collagen recognition
[67] and increasing the threshold for NK cell activation.
In contrast to LAIR-1, glycoprotein VI which is found on
platelets also binds to collagen and through its association
with the FcRγ chain, an activation signal is induced which
leads to increased thrombosis. Recently the crystal structure
of LAIR-1 was determined and the collagen binding site was
mapped(Brondijketal.,2010).LAIR-1ismadeupofasingle
E-type Ig-like fold made up of two β-sheets consisting of β-
strands ABE and A GFCC  with high structural homology
to the D1 domain of KIR2DL2 (rmsd: 1.34 ˚ A), ILT11 (rmsd:
1.36 ˚ A), and GP VI (rmsd: 1.09 ˚ A). Using mutagenesis and
bindingexperimentsinadditiontoNMRresidueassignment
signal shifts, it was possible to map the collagen binding
site onto the A FGCC β-sheet speciﬁcally involving residues
Arg59 and Glu61 from the LAIR-1 F strand and Trp109
and Glu111 from the G strand (Figure 4(d)). The collagen
binding site of LAIR-1 is quite diﬀerent to the site proposed
for GP VI, and this may allow the design of molecules
which can act as immune modulators by blocking LAIR-1 or
aﬀecting thrombosis via GP VI collagen binding.
3.C-TypeLectin-LikeNK Receptors
Many NK receptor structures exhibit a C-type lectin fold,
similar to that found among carbohydrate binding animal
lectins and whose function requires bound calcium ions.
Most C-type lectin-like NK receptors recognize membrane-
bound protein ligands independent of carbohydrates and do
not require calcium for their ligand recognition. Examples
include CD69, CD94/NKG2 receptors which recognize HLA-
E, NKG2D which recognizes stress-induced and tumor
ligands such as MICA/B and ULBPs. In mouse, the classical
class I MHC recognizing receptors, the Ly49 family receptors
as well as Nkrp1 receptors, are also C-type lectin-like
molecules. Within this review, we shall focus on the struc-
tures of human CD94/NKG2, NKG2D and their mechanisms
of ligand recognition.
3.1. The Structure of the CD94/NKG2 Receptor and Its Recog-
nition of HLA-E. CD94 exists primarily in a heterodimeric
form with NKG2A, C, and E on the cell surface. Depending
on the associated NKG2 subunit, CD94/NKG2 can function
as either an activating (NKG2C, and E) or an inhibitory
(NKG2A) receptor. The inhibitory form has intracellular
immunoreceptor tyrosine-based inhibitory motifs (ITIM),
while the activating forms contain a positive transmembrane
charged residue which facilitates interaction and signaling
through the ITAM-containing DAP12 molecule. HLA-E was
identiﬁed as the ligand for CD94/NKG2 [68–70]. Since C-
type lectins are historically associated with carbohydrate
binding, it was not clear how CD94/NKG2 would recognize
HLA-E and whether the recognition involved the glycosyla-
tion of the class I MHC. In addition, the only class I binding
receptors known at the time were T cell receptors, which
are members of the immunoglobulin superfamily.Thus, part
of the need to solve the CD94 structure was to understand
how a C-type lectin fold receptor could recognize an MHC
ligand. The crystal structure of a homodimeric human CD94
showed that the receptor maintained a canonical C-type
lectin fold except that one of the two α-helices in the canon-
ical C-type lectin fold (helix 2) was missing and replaced
withaloopinthestructureofCD94(Figure 7(a))[17].More
importantly, the CD94 structure showed that the receptor is
missing four of the ﬁve calcium binding ligands and does not
haveaboundcalciumioninitsputativecalciumbindingsite.
Thus, the structural identiﬁcation suggested that the C-type
lectin-like NK receptors functioned diﬀerently from a typical
lectin calcium and carbohydrate binding molecule.
CD94/NKG2A binding of HLA-E by NK cells is critical
for the careful monitoring of MHC class I expression on
healthy cells. HLA-E molecules present peptides which have
been generated from digested MHC class I molecules and
the CD94/NKG2A complex detects this HLA-E/MHC class
I peptide complex. This mechanism serves as a double-check
to ensure that MHC class I molecules are being produced
by a cell in a normal manner. Upon NKG2A/CD94 ligand10 Journal of Biomedicine and Biotechnology
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Figure 7: Structure of CD94 and associated complexes. (a) CD94 monomer shown in cartoon representation. (b) NKG2A/CD94
heterodimer structure with NKG2A shown in light blue and CD94 shown in green cartoon representation with each α-helix from both
molecules colored red. (c) NKG2A shown in cartoon representation rotated 90◦ in relation to (7B) displaying interacting residues in ball and
stick representation. Residues colored in green are part of interaction region 1 described in the text while residues colored salmon are part
of region 2 also described in the text. (d) CD94 in cartoon representation rotated 90◦ in relation to (B) with residues colored yellow part of
interaction region 1 while residues colored in grey are part of interaction region 2. (e) Cartoon representation of NKG2A/CD94 in complex
with peptide bound HLA-E molecule. The bound peptide is shown in ball and stick representation with oﬀ-white carbon atoms (f) HLA-E
molecule rotated 90◦ from (7E) illustrating the HLA-E interaction surface with residues which form bonds with NKG2A and CD94 shown
in light blue coloring, and green coloring, respectively. Bound peptide is also shown in ball and stick representation. (g) NKG2A/CD94
molecule rotated 90◦ from (7E) showing the HLA-E interaction surface with the bound peptide shown for reference, residues which interact
with HLA-E and the peptide are shown colored green in ball and stick representation.
binding of the HLA-E/peptide complex an inhibitory signal
istransducedviacytoplasmicITIMmotifsfoundonNKG2A.
The crystal structure of CD94/NKG2A ﬁrst showed us how
this heterodimeric complex is constructed [18]. The dimer
interface between NKG2A and CD94 is extensive (1500 ˚ A)
and is made up of largely polar interactions with salt bridge
formation observed at the edge of the dimer interface and
a further central hydrophobic area maintaining the dimer
(Figures 7(b), 7(c), and 7(d)). CD94/NKG2A dimerization is
also driven by extensive main chain interactions between the
β1 strands of both molecules, thus leading to the formation
of a β-sheet made up of three β-strands from one molecule
and three from the adjacent molecule.
Most recently, the structure of CD94/NKG2A in com-
plex with HLA-E with a bound HLA-G peptide has been
determined [19, 20]. The structure of CD94/NKG2A doesJournal of Biomedicine and Biotechnology 11
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Figure 8: Structure of NKG2D homodimer and associated complexes. (a) NKG2D homodimeric structure. (b) NKG2D in the same
orientation as (a) in complex with the two domain MICA molecule. (c) NKG2D in complex with ULBP3. (d) MICA structure rotated
90◦ in orientation relative to (b); residues forming hydrogen bonds with NKG2D are shown in ball and stick representation with red
carbon and blue nitrogen atoms while residues forming hydrophobic interactions are shown in yellow transparent surface representation.
(e) NKG2D structure rotated 90◦ in orientation relative to (b); residues forming hydrogen bonds with MICA are shown in ball and stick
representation with red carbon and blue nitrogen atoms while residues forming hydrophobic interactions are shown in green transparent
surface representation. (f) ULBP3 structure rotated 90◦ in orientation relative to (c); residues forming hydrogen bonds with NKG2D are
shown in ball and stick representation with red carbon and blue nitrogen atoms while residues forming hydrophobic interactions are shown
in yellow transparent surface representation. (g) NKG2D structure rotated 90◦ in orientation relative to (b); residues forming hydrogen
bonds with ULBP3 are shown in ball and stick representation with red carbon and blue nitrogen atoms while residues forming hydrophobic
interactions are shown in green transparent surface representation.
not undergo any structural rearrangements upon ligand
binding,indicatingthatalockandkeymechanismofbinding
is used. NKG2A and CD94 interact with the α2a n dα1
helices of HLA-E, respectively, with the presence of charge
complementarity between the ligand and receptor clearly
evident such that 8 salt bridges and 19 H bonds are observed;
there is also a small hydrophobic patch in the ligand receptor
interface. The buried surface area is very large (2100 ˚ A) with
the majority of it contributed by CD94. In addition, the
surface complementarity is higher for CD94 interactions
with HLA-E (0.68 versus 0.31 for NKG2A). Overall, the
peptide makes up 23% of the ligand receptor interface, and
again CD94 is dominant in its interactions with the peptide
(80%) with CD94 interacting with the P5-Arg, P6-Thr, and
P8-Phe while NKG2A only interacts with the P5-Arg.
3.2. Activating Receptor NKG2D and Its Ligand Bound
Structures. The ﬁrst NKG2D structure reported was that of
the murine NKG2D homodimer [21], and, subsequently,
both human and murine NKG2D structures were reported12 Journal of Biomedicine and Biotechnology
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Figure 9: (a) Structure of KLRG1 in complex with E-cadherin shown in cartoon representation with the critical KLRG-1 loop regions
which interact with the E-cadherin A  and G sheet regions labeled. (b) Cartoon representation of the heterotrimeric NKG2C DAP12
transmembrane complex with interacting residues shown in ball and stick representation with bonding network shown by dashed lines.
(c) View from above the membrane showing a closeup of the interacting residues and bonding interactions.
in complexes with their respective ligands, including ULBP3,
MICA, and Rae-1β [22–24]. Similar to the CD94 receptor,
the second α-helix in NKG2D is also distorted into a
one-turn helix (Figure 8(a)) and the receptor does not
have a functional calcium binding site, which was also
demonstrated for the mouse C-type lectin-like Ly49 family
of receptors [71].
NKG2D binds to a number of proteins which have high
structural homology to the α1a n dα2 domains of MHC class
I molecules. Although the overall orientation of the NKG2D
ligand bound structures are highly similar (Figure 8), there
are very speciﬁc diﬀerences in the residues which interact
with MICA compared to those seen in the ULBP3 complex.
The homodimeric structure of NKG2D forms a central
concave surface on its membrane distal face which allows the
elevated central α-helices of the MHC class I homologues to
bind NKG2D. The major binding region between the ligands
MICA and ULBP3 and NKG2D receptor involves the c-
terminal part of the α1 helix and the n-terminal region of the
α3 helix of the ligands (Figure 8) .N K G 2 Du t i l i z e si d e n t i c a l
loopregionsfrombothofitssubunitstobindtheligand,and
there is minimal structural reorganization following ligand
binding. The binding interface between NKG2D ligands
is extensive (1930 ˚ A ULBP3 complex and 2180 ˚ AM I C A
complex) and also quite speciﬁc (shape complementarity:
0.65ULBP3 complex; 0.72MICA complex) resulting in
strong binding between the receptor and ligands. Analysis
of the orientation of the two complexes indicates there is a
subtle diﬀerence in the angle of orientation of ULBP3 and
MICA on NKG2D resulting in a 6◦ diﬀerence. Interestingly,
due to this slight change in the binding, it results in a
diﬀerence in the number of hydrogen bonds between the
complexes even though the strongest hydrogen bonds are
conserved. In addition to the hydrogen bonding pattern,
there is also an extensive hydrophobic region involved in
ligand binding.
3.3. Other C-Type Lectin-Like NK Cell Receptors. In addi-
tion to the well-studied inhibitory molecules KIR proteins
and also the collagen binding inhibitory molecule LAIR-1,
killer cell lectin-like receptor G1 (KLRG1) is an additional
inhibitory molecule [72]. KLRG1 contains an extracellular c-
typelectin-likereceptor,a19aminoacidstalkregion,asingle
transmembrane domain, and a cytoplasmic ITIM domain
allowing the elicitation of an inhibitory signal within NK
cells [73]. KLRG1 is found on the vast majority of NK cells,
and, interestingly, surface expression is highly upregulated
following viral or parasitic infection [74]. Most recently
KLRG1 has been shown to interact with E-, N, and R-
cadherins [75]. E-cadherin is a critical molecule found in
the junction between epithelial cells where it mediates tight
contactswhileN-andR-cadherinsperformsimilarfunctions
with diﬀerent cell types. In the presence of KLRG1/E-
cadherin interactions, NK cell lysis is prevented. Relevant to
NK surveillance of transformed cells, epithelial cells which
have become malignant typically have reduced cadherin
expression which in turn promotes tumor invasiveness and
subsequent metastasis [76]. The crystal structure of KLRG1
in complex with E-cadherin has recently been determined
and provides a clear understanding of KLRG interaction
with E-cadherin [25]. KLRG-1 binds to E-cadherin with
a relatively low aﬃnity (100–200μM). KLRG1 structure isJournal of Biomedicine and Biotechnology 13
similar to other c-type lectin domains such as NKG2D made
up of two alpha helices, two antiparallel beta sheets and the
presence of intermolecular disulphide bonds.
KLRG1 binds to E-cadherin by using three loop regions
(L3, L4, and L6) and β strand 4 which interact with the
cadherin short A  and G β strands similar to other CTLD
receptors such as NKG2D with the binding characterized
by exemplary surface complementarity and an extensive
hydrogen bonding network (Figure 9(a)). The low aﬃnity of
KLRG-1 to a single cadherin domain may be overcome by
multiple copies of KLRG-1 binding to the multiple domains
of E-cadherin.
4. Transmembrane SignalingComplexes
Following ligand binding NK cell receptors initiate a sig-
naling cascade which results in cell activation or inhibition.
Critical to NK cell activation is the association of the
transmembrane region of NK receptors with a signaling
molecule containing an ITAM motif or association with
adaptor molecules with a YXXM motif. The association of
a NK activating receptor with an ITAM-containing adaptor
molecule is mediated through transmembrane interactions
and has recently been structurally characterized [26]. Uti-
lizing solution NMR, the heterotrimeric structure of the
transmembrane association of DAP12 with NKG2C was
determined. The signaling assembly made up of a sophis-
ticated electrostatic network involves a pair of aspartate
residues from the DAP12 dimer, two adjacent threonine
residues which together form the speciﬁc interaction with
the lysine residue of NKG2C (Figures 9(b) and 9(c)).
Mutagenesis and sequence analysis indicates that a very
similar mechanism of heterotrimeric association occurs in
the NKG2D-DAP10 complex formation. The interaction of
CD16withtheCD3ζ andFcεRIγ aswellasanumberofother
NK cell receptor and adaptor complexes is currently not
structurally characterized, and this information will provide
detailed understanding of the critical passage from ligand
binding to cell activation.
This review has outlined the current state of human
NK cell receptor structural biology. The structures which
have been determined allow us to gain an understanding of
the complex mechanisms involved in ligand recognition and
NK cell activation and inhibition. Further high-resolution
structure studies are likely over the next few years and
remain eagerly anticipated in an eﬀort to answer a number
of burning questions within NK cell biology.
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